Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 123Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Myelodysplastic Syndromes 101Lymphoma, Non-Hodgkin 94Leukemia, Lymphocytic, Chronic, B-Cell 94Hodgkin Disease 88Multiple Myeloma 82Leukemia 73Lymphoma, Mantle-Cell 63Lymphoma, Follicular 62Lymphoma 62Lymphoma, Large B-Cell, Diffuse 59Myeloproliferative Disorders 55Lymphoma, B-Cell, Marginal Zone 55Leukemia, Myelogenous, Chronic, BCR-ABL Positive 54Burkitt Lymphoma 50Leukemia, Myelomonocytic, Chronic 48Congenital Abnormalities 46Leukemia, Myeloid, Chronic-Phase 45Lymphoma, Large-Cell, Immunoblastic 42Leukemia, Myeloid, Accelerated Phase 39Anemia, Refractory, with Excess of Blasts 36Hematologic Neoplasms 35Waldenstrom Macroglobulinemia 34Primary Myelofibrosis 34Graft vs Host Disease 34Blast Crisis 31Neoplasms, Plasma Cell 30Recurrence 28Dendritic Cell Sarcoma, Interdigitating 28

Interventions

Cyclophosphamide 3thymoglobulin 2fludarabine 2Rituximab 2Melphalan 2Busulfan 2fludarabine phosphate 1Whole-Body Irradiation 1Thiotepa 1Tacrolimus 1Sugammadex 1Mycophenolic Acid 1Levetiracetam 1Dexamethasone 1Bortezomib 1Antilymphocyte Serum 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × beta-Thalassemia × Mycophenolic Acid × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡